Whereas IRF-5 contributes to the anti-cancer response as a regulator of cell growth and apoptosis [74,75], IRF-9 may contribute to survival of cancer cells through upregulation of IL-6 [76], indicating that activation of p53 in the TME should be completed via rational combination therapies to avoid potential pro-cancer effects. Here, IRF5 is linked to cancer.